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Prevention remains an important strategy to reduce the burden of cancer. One 
approach to prevent cancer is the use of phytochemicals in various combinations as safe 
and effective cancer preventative agents. The purpose of this study was to examine the 
effects of the topical combination of ursolic acid (UA) and curcumin (Curc) for potential 
combinatorial inhibition of skin tumor promotion using the mouse two-stage skin 
carcinogenesis model. Furthermore, UA, Curc and resveratrol (Res) were evaluated for 
their ability to inhibit skin tumor promotion when given in the diet alone and in 
combination.  
In short-term experiments, the combination of UA and Curc pretreated topically 
inhibited TPA-induced activation of epidermal EGFR, p70S6K, NF-κB p50, Src, c-Jun, 
Rb, c-Fos and IκBα. Levels of c-Fos, c-Jun and Cox-2 were also significantly reduced by 
the combination. The alterations in these signaling pathways by the combination of UA 
and Curc were associated with decreased epidermal proliferation as assessed by measuring 
BrdU incorporation. Significant effects were also seen with the combination on epidermal 
 vi 
and inflammatory gene expression and dermal inflammation with the greatest effects on 
expression of IL-1β, IL-6, IL-22 and CXCL12. Furthermore, results from skin tumor 
experiments demonstrated that the combination of UA and Curc given topically 
significantly inhibited mouse skin tumor promotion by TPA to a greater extent than the 
individual compounds given alone.  
Initial short term experiments suggested UA, Curc and Res given in the diet alone 
or in combination inhibited TPA-induced EGFR, c-Jun, NF-κB p50, Cox-2 and Rb. 
Furthermore, Curc and Res, given alone and in combination with UA, inhibited TPA-
induced hyperproliferation. However, in the two-stage skin carcinogenesis model none of 
the compounds given in the diet alone or in combination inhibited tumor multiplicity or 
tumor incidence at the dose give. Res alone did significantly inhibit tumor size and weight 
to levels comparable with Met, indicating it is inhibiting tumor growth, but not initial tumor 
development. 
These results demonstrate the potential cancer chemopreventive activity and 
mechanism(s) for the combination of topically applied UA and Curc.
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Chapter 1: Introduction and Background 
1.1 CHEMOPREVENTION 
Despite the many advances that have been made in understanding cancer and 
developing new therapies, cancer is still the second leading cause of death in the US and 
accounts for about one in four deaths. Furthermore, approximately two out of five people 
will develop cancer in their lifetime, and in many cases cancer can be preventable (1). 
Aside from lifestyle choices such as avoiding tobacco products and maintaining a lean 
bodyweight, chemoprevention remains a strategy to reduce cancer risk, especially in high-
risk populations. Chemoprevention is the use of natural, synthetic, or biological agents to 
reverse, suppress, or prevent the initial development of carcinogenesis or the progression 
to metastatic cancer (2).  
Epidemiological and meta-analysis studies have been conducted exploring 
consumption of fruits and vegetables as chemopreventive measures. For example, in breast 
cancer, one meta-analysis study found high consumption of vegetables was associated with 
a reduced relative risk, another looked specifically at cruciferous vegetable intake and 
found an inverse correlation and an epidemiological study demonstrated that eating grapes 
correlated with a decreased risk of breast cancer risk (3-5). A case-control study 
investigating the relative risk of prostate cancer found a reduced risk with consumption of 
yellow or orange vegetables, particularly corn and carrots, cruciferous vegetables or 
legumes (6). Another epidemiological study found an inverse correlation between high 
consumption of fruit, dark-green vegetables, deep-yellow vegetables or onions and garlic 
and risk of colorectal adenoma, which can eventually develop into colorectal carcinomas 
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(7). Overall these studies and others demonstrate a high consumption of fruits and 
vegetables can decrease the relative risk of developing certain cancers and is thought to be 
attributed, at least in part, to their naturally occurring phytochemicals (8). 
Many studies to date have examined phytochemicals as chemopreventive agents 
due to their ability to act on a broad spectrum of signaling pathways and their relatively 
low toxicity (8-11). Phytochemicals have been shown to inhibit all stages of cancer 
development including initiation, promotion and progression. Many phytochemicals, such 
as sulforaphane, resveratrol and various flavonoids, can prevent initiation by inhibiting 
enzymes involved in phase I metabolism of pro-carcinogens into carcinogens, namely 
cytochrome P450 (CYP450) enzymes, and activating detoxifying phase II enzymes such 
as glutathione reductase, glucuronosyltransferase and thioredoxin reductase (12-15). 
During promotion and progression, various phytochemicals can impede oncogenic 
transcription factors, growth and proliferation signaling cascades, inflammation and 
metastasis by inhibiting targets such as Forkhead Box M1 (FOXM1), Wnt/β-catenin, Stat3, 
NF-κB, PI3K/Akt/mTOR, EGFR, MAPKs, androgen receptors and estrogen receptors 
(10,16-19). Furthermore, phytochemicals such as EGCG, genistein and sulforaphane have 
been shown to provide cancer preventive effects through epigenetic regulation by altering 
expression of DNA methyltransferases and histone deacetylases (20,21).  
1.2 TWO-STAGE SKIN CARCINOGENESIS MODEL 
The two-stage skin carcinogenesis model is a well-established model that mimics 
the multistage nature of many human cancers and allows us to examine the various stages 
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of cancer development from initiation, to promotion and finally progression (22). 
Furthermore, we can use this model to see how phytochemicals affect these different stages 
of cancer and whether they would be effective as chemopreventive agents.  
In this model, a sub-carcinogenic dose of an initiating agent, such as 7,12-
dimethylbenz[a]anthracene (DMBA), is first applied topically to the backs of the mice (22). 
During this initiation step, a mutation occurs primarily in the Hras gene, often causing an 
A to T transversion in codon 61 (22,23). This mutation persists for the lifetime of the 
animal, but does not cause tumorigenesis alone (22). The keratinocyte stem cells are 
thought to be the main target of DMBA initiation (24). 
The next stage is promotion, in which a promoting agent, such as the phorbol ester 
12-O-tetradecanoylphorbol-13-acetate (TPA), is repeatedly applied topically (22). This 
promotion phase is reversible if treatment is not continued and results in hyperplasia, 
hyperproliferation, increased DNA synthesis and an increase in inflammation (22). This 
ultimately results in clonal outgrowths called papillomas (22). TPA activates protein kinase 
C (PKC), which is thought to mediate some of its effects by activating ornithine 
decarboxylase (ODC) and epidermal growth factor receptor (EGFR) (25). The promotion 
stage is the most amendable to chemoprevention because it reversible and occurs over a 
long period of time. 
During the progression stage, which can occur independently of continued 
treatment with a tumor promoter, there is an accumulation of additional genetic changes 
and dysplasia, and some of the papillomas can convert to squamous cell carcinoma (SCC) 
(22).  Ultimately the SCCs can invade the basement membrane and metastasize (22). 
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1.2.1 Skin Tumor Promotion by TPA 
 TPA treatment causes an increase in edema, inflammation and proliferation and 
alters gene expression and enzyme activities in signaling pathways involved in 
tumorigenesis (22,25,26). With a single treatment of TPA, leukocytes, macrophages and 
neutrophils begin to infiltrate into the dermis, and the number of dendritic cells increases, 
contributing to an inflammatory response (25-27). The expression of several chemokines 
and cytokines are also upregulated. For example, CXCL2, Cox-2 and TNF-α are 
upregulated during TPA treatment and a thought to be mediated, at least in part, via 
activation of PKCα (28). The role of TNF-α seems to be essential in TPA-induced 
inflammation and in DMBA/TPA-induced carcinogenesis. TNF-α knockout mice were 
resistant to tumor development in the two-stage carcinogenesis model and TPA-induced 
proliferation. Moreover, the TNF-α knockout mice had decreased neutrophil and 
eosinophil infiltration into the dermis (27). 
As shown in Figure 1.1, TPA binds to and activates PKC, which is thought to 
mediate many of the effects during skin tumor promotion (25). TPA activation of PKC 
induces epidermal ODC, the rate limiting enzyme in polyamine synthesis. This increases 
the levels of putrescine and spermidine and allows for increased DNA synthesis (25,29,30). 
PKC also activates the Ras/Raf/mitogen-activated protein kinase (MAPK) pathway 
through phosphorylation of Raf, leading to increased cellular proliferation (26,31-33). In 
addition, PKC phosphorylates and activates c-Jun N-terminal kinase (JNK) (34). In turn 
JNK can increase levels of c-Jun and c-Fos, by phosphorylating and activating transcription 
factors responsible for their transcription, as well as phosphorylate and activate c-Jun (c- 
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Figure 1.1: TPA activates PKC to mediate tumor promoting effects  
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Jun can also activate transcription of itself in partner with ATF2) (35). Finally, PKC has 
also been shown to activate NF-κB signaling by phosphorylating IκB Kinase β (IKKβ) 
(36). 
 EGFR is a receptor tyrosine kinase that is overexpressed in many human cancers, 
including glioblastomas, lung cancer, esophageal cancer and breast cancer (37-40). 
Furthermore, EGFR is known to play a critical role in skin tumor promotion by TPA. EGFR 
ligands such as heparin-binding epidermal growth factor (HB-EGF), amphiregulin (AR) 
and transforming growth factor-alpha (TGFα) have been shown to be upregulated by TPA 
in the two-stage skin carcinogenesis model, leading to an increase in phosphorylation and 
activation of EGFR (Figure 1.2) (41-43). Moreover, transgenic mice expressing a 
dominant negative form of EGFR in the basal layer of the epidermis were resistant to tumor 
growth (44). EGFR mediates its tumor promoting activity by activating a signaling cascade 
of pathways such the Ras/Raf/MAPK, PI3K/Akt/mTOR and STAT3 pathways, leading to 
cell proliferation, survival tumor growth (45,46). 
IFG-1R is another important growth factor signaling pathway that gets activated during 
skin tumor promotion by TPA (47). IGF-1 signaling is upregulated in many human cancers, 
including lung cancer, colorectal cancer, pancreatic cancer and breast cancer, and plays an 
important role in cell proliferation and inhibition of apoptosis (48). Notably, one of the 
signaling cascades this activates is the PI3K/Akt/mTOR pathway (49). mTORC1 is a 
highly conserved serine/threonine kinase that regulates cell growth, proliferation, protein 
translation, and autophagy via serine/threonine phosphorylation on downstream targets, 
such as p70S6K, 4EBP1 and ULK1 (50,51).  
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Figure 1.2: TPA activates growth factor signaling pathways  
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 AP-1 is a transcription factor composed of Jun and Fos family members and plays 
a role in various processes during tumorigenesis, including differentiation, proliferation, 
and transformation (52). It can activate transcription of proteins involved in these processes 
such as keratinocyte growth factor, cyclin D1 and MMP-9 and inhibit transcription of p53 
(53-57). AP-1 is highly involved in keratinocyte differentiation and proliferation (58). It 
also plays an important role in skin tumor promotion by TPA. In a mouse model using an 
AP-1 inhibitor, mice developed significantly less tumors in the two-stage skin 
carcinogenesis model (59). 
 NF-κB signaling plays an essential role in inflammation and cancer. Ligands such 
as IL-1β and TNFα can active Toll-like receptors (TLRs), Interleukin-1 receptor (IL-1R), 
tumor necrosis factor receptor (TNFR) and antigen receptors, leading to the 
phosphorylation of IκB kinase (IKK)(60). Additionally, as mentioned above, PKC can 
directly phosphorylate IKK (36). IKK then phosphorylates inhibitor of κB (IκB), targeting 
it for proteosomal degradation, allowing NF-κB p65 and p50 to enter the nucleus and 
activate transcription of genes (60). NF-κB signaling is highly involved in skin tumor 
promotion by TPA. Mice with an epidermal keratinocyte-specific deletion of NF-κB p65 
developed significantly less tumors in the two-stage skin carcinogenesis assay using 
DMBA and TPA. Furthermore the absence of p65 in the epidermis inhibited TPA-induced 
hyperplasia and hyperproliferation (61). In addition, mice with a deletion of Cox-2, whose 
transcription is activated by NF-κB, were resistant to the two-stage skin carcinogenesis 
model. Moreover, Cox-2 deficient mice had reduced TPA-induced hyperplasia and 
hyperproliferation (62). Mice overexpressing Cox-2 developed papillomas after a single 
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treatment of a subcarcinogenic dose of DMBA and did not require a tumor promoting agent 
to be applied (63). These studies highlight the importance of NF-κB, particularly Cox-2, 
signaling during the tumor promotion phase. 
1.3 URSOLIC ACID 
UA is a pentacyclic triterpenoid found in plants and herbs such as Perilla 
frutescens, rosemary, cranberries and the peels of apples (64,65). UA, like other 
pentacyclic triterpenoids, has been shown to have many beneficial effects such as anti-
inflammatory, antioxidant, anti-proliferative, anti-cancer, and antimicrobial effects 
(65,66). It has been shown in mouse models to inhibit various types of cancer including 
non-melanoma skin cancer, breast cancer, prostate cancer, pancreatic cancer and leukemia 
(67-74). 
It has been demonstrated that UA can inhibit the PI3K/Akt/mTORC pathway. In 
vitro, UA was shown to decrease total levels of PI3K and phosphorylation of Akt in breast 
cancer cell lines T47D, MCF-7 and MDA-MB-231 and in pancreatic cell line MIA PaCa-
2 (74,75). UA also increased phosphorylation of AMPK and decreased phosphorylation of 
mTOR and Akt in HepG2 liver cancer cells (76). In a colorectal cancer xenograft model, 
UA decreased phosphorylation of Akt and p70S6K in the tumor tissue (77). 
UA can also inhibit NF-κB signaling. UA decreased total levels of IKKα and IκBα 
and decreased phosphorylation of NF-κB p65 in T47D, MCF-7 and MDA-MB-231 breast 
cancer cells. Furthermore, this inhibition of NF-κB signaling was thought to contribute to 
a reduction of levels of TNF-α, IL-6, IL-1β, IL-18 and IFN-γ (75). In a dextran sulfate 
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sodium induced colitis mouse model, UA protected against colitis, in part, by decreasing 
levels of nuclear NF-κB p65 (78). UA also inhibited carbon tetrachloride induced 
nephrotoxicity and hepatotoxicity in mice and decreased levels of nuclear NF-κB p65 
(79,80). 
Another mechanism by which UA provides anti-tumor effects is by inducing 
apoptosis. UA has been shown to induce apoptosis in a number of cell lines, including 
prostate cancer, pancreatic cancer, leukemia and breast cancer (70,72-75,81). Shanmugam 
et al. found UA increased DNA-fragmentation and annexin V staining in DU145 and 
LNCaP cells. Furthermore, when DU145 cells were injected in male nude mice, UA 
administered i.p increased caspase 3 expression in the prostate tumor tissue (70). The same 
group found that UA given in the diet in a transgenic adenocarcinoma of mouse prostate 
model increased caspase 3 expression in the dorsolateral prostate, which was thought to 
mediate some of UA’s  anti-tumor activity (71).  
1.3.1 UA Activity in the Skin 
UA inhibits TPA induced inflammation of the skin (64). Furthermore, UA has been 
shown to inhibit skin tumor promotion by TPA. Specifically, UA applied topically prior to 
TPA treatment significantly reduced the number of papillomas during the two-stage skin 
carcinogenesis protocol when initiated with DMBA (67,68,82,83). Our lab has shown that 
in short term experiments when UA was treated prior to TPA twice weekly for two weeks, 
UA significantly inhibited TPA-induced proliferation and hyperplasia by inhibiting various 
signaling pathways that are upregulated by TPA. UA decreased TPA-induced 
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phosphorylation of NF-κB p65, Akt and JNK 1/2 as well as levels of Cox 2. In addition, 
UA inhibited TPA-induced infiltration of mast cells and CD45+ cells (67,68). Finally, UA 
decreased TPA-induced gene expression of inflammatory markers such as Cox-2, CXCL2 
and IL-6 (67,68,83). 
1.4 CURCUMIN 
 Curcumin (Curc), a polyphenol found in turmeric, has been shown to possess anti-
inflammatory, anti-proliferative and antioxidant activity, which are thought to play major 
roles in curcumin’s chemoprevention action (84). Curc has been shown in a number of 
mouse models to inhibit tumorigenesis, including non-melanoma skin cancer, colorectal 
cancer, lung cancer and glioma (85-88). 
 Curc has been shown to inhibit NF-κB signaling in numerous instances, which 
contributes to its anti-tumor activity. In early studies, Curc was shown to inhibit NF-κB 
binding activity in ML-1a cells (human myelomonoblastic leukemia cells) and HT-29 cells 
(human colonic epithelial cells) (89,90). More recent studies have continued to demonstrate 
this. For example, in human colon SW480 and LoVo cells, Curc inhibited NF-κB binding 
activity, which was thought to contribute to decreasing levels of matrix metalloproteinase-
9 (MMP9) and urokinase-type plasminogen activator (uPA) (91). In human pancreatic 
cancer BxPC-3 and Panc-1 cells, Curc inhibited hydrogen peroxide induced 
phosphorylation of NF-κB and levels of MMP2 and MMP9 (92). Curc also inhibited NF-
κB activity and decreased level of MMP-9 in human osteoclastoma cells (93). 
Another well-known target of Curc is Stat3. Bharti et al. were one of the first groups 
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to demonstrate this and showed that Curc inhibited constitutive phosphorylation of Stat3 
and translocation of Stat3 to the nucleus in human multiple myeloma cell line U266 (94). 
More recently, our group has shown that Curc inhibits phosphorylation of Stat3 in mouse 
prostate cancer HMVP2 cells (95). In a human non-small cell lung cancer ectopic xenograft 
model, Curc treatment decreased tumor growth and phosphorylation of Stat3 in the tumor 
tissue (96). 
Curc has also been shown to induce apoptosis in a variety of cells. Curc induced 
caspase-3 activity in human osteoclastoma cells (93). In HT-29 colon adenocarcinoma 
cells, Curc increased the number of apoptotic cells, which was thought to be induced by an 
increase in reactive oxygen species (ROS) (97). Curc also decreased levels of anti-
apoptotic protein Bcl2 and increased levels of apoptotic proteins Bax, caspase 8, cleaved 
caspase 9 and cleaved caspase 3 in breast cancer stem cells from SUM159 and MCF7 tumor 
spheres (98). In melanoma cell lines, Curc increased apoptosis in a manner independent of 
p53 by activating the Fas death receptor (99).  
1.4.1 Curcumin Activity in the Skin 
Curc has been shown to have anti-inflammatory effects in the skin and to inhibit 
tumor development in the two-stage skin carcinogenesis model (85,100). In one study, 
Curc was shown to inhibit skin tumor promotion by TPA by a strong anti-oxidant effect as 
shown by a significant reduction in the formation of the oxidized DNA base 5-
hydroxymethyl-29-deoxyuridine and the production of hydrogen peroxide. Curc also 
inhibited DNA synthesis in this study (85). Furthermore, Curc has been shown to inhibit 
Cox activity as shown by a decrease in metabolism of arachidonic acid to prostaglandin E2 
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(PGE2) and prostaglandin F2α (PGF2α) (100). In another study, Curc decreased TPA-
induced mRNA levels of c-Jun, c-Fos and c-Myc (101).  
1.5 RESVERATROL 
Resveratrol (Res) is a polyphenol phytoalexin found in many plants, including 
grapes, berries, plums and peanuts (102). Like UA and Curc, Res also has anti-
inflammatory, antioxidant and anti-proliferative effects (102). Res has been shown to 
inhibit tumorigenesis in many rodent models, such as skin, colon, breast, liver, pancreatic 
and prostate cancer (103-108). Initial studies demonstrated the chemopreventive effects of 
Res due to its ability to inhibit Cox-1 and Cox-2 activity, inflammation and free radical 
formation. Subsequently, Res was able to inhibit skin tumor promotion by TPA (103). 
Furthermore, our lab has shown Res inhibited TPA-induced phosphorylation of NF-κB p65 
and Akt and others have shown Res inhibited TPA-induced AP-1 activity (67,109). In 
squamous cell carcinoma cells Ca3/7, Res protected against oxidative DNA damage and 
inhibited activity of the cytochrome P450 (CYP) enzymes CYP1A1 and CYP1B1 (13).  
1.6 METFORMIN 
Metformin (Met) is a common diabetes medication and has been shown in 
retrospective studies to reduce cancer incidence in type II diabetic patients (110). 
Additionally, several mouse model studies have corroborated the association of metformin 
and cancer prevention (111-114). Metformin activates AMPK and as a result leads to 
reduced gluconeogenesis (115). AMPK negatively regulates the PI3K/Akt/mTORC1 
pathway (116). As mentioned above, this pathway regulates cell growth, proliferation, 
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protein translation, and autophagy (50,51). Our lab has previously shown that Met inhibits 
skin tumor promotion by TPA (111). In this study, Met significantly decreased TPA-
induced serum insulin levels in obese mice and reduced epidermal hyperproliferation and 
hyperplasia. Furthermore, Met inhibited the PI3K/Akt/mTOR pathway by activating 
AMPK and producing a subsequent decrease in phosphorylation of p70S6K and S6 
ribosomal and increase in levels of the tumor suppressor Pdcd4 (111). 
  
 15 
Chapter 2: Materials and Methods 
2.1 ANIMALS AND DIETS 
Female ICR (CD-1) (Envigo, Indianapolis, IN) were fed ad libitum and group 
housed for all experiments. For all topical experiments, mice were maintained on a regular 
chow diet. For the diet study short term experiments, mice were maintained on an AIN-
76A diet with or without UA (2 g/kg), Res (5 g/kg) and Curc (10 g/kg). For the diet study 
two-stage skin carcinogenesis experiments, mice were maintained on an AIN-93M diet 
with or without UA (2 g/kg), Res (5 g/kg) and Curc (10 g/kg). All animal experiments were 
performed according to protocols approved by The University of Texas at Austin 
Institutional Animal Care and Use Committee. 
2.2 CHEMICALS 
For the topical experiments, UA (90%) was purchased from Sabinsa (East Windsor, 
NJ) and Curc (≥65%) was purchased from Sigma Aldrich (St. Louis, MO). UA (98%) and 
Curc (95%) used for incorporation into the diets were purchased from Standford Chemicals 
(Irvine, CA). Res (99%) for incorporation into the diets was purchased from Mega 
Resveratrol (Danbury, CT). DMBA (≥95%) and 5-Bromo-2′-deoxyuridine (BrdU) (≥99%) 
were purchased from Sigma Aldrich (St. Louis, MO). TPA (>99.5%) was purchased from 
LC Laboratories (Woburn, MA). 
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2.3 TWO-STAGE SKIN CARCINOGENESIS 
 2.3.1 Topical experiment 
 As shown in Figure 2.1, female ICR mice 7 weeks old (n = 30/group) were shaved 
on the dorsal skin and then two days later initiated topically with 25 nmol DMBA. Two 
weeks after initiation with DMBA, mice were pretreated topically with acetone (Ace) 
vehicle, UA (1 μmol), Curc (2 μmol) or a combination of UA (1 μmol) and Curc (2 μmol) 
prior to TPA (6.8 nmol) treatment (UA was applied 15 minutes prior and Curc was applied 
30 minutes prior to TPA). All treatments were given twice-weekly for the duration of the 
experiment (25 weeks). Bodyweight and tumor incidence (percent of mice with 
papillomas) were measured once a week, and tumor multiplicity (average number of 
papillomas per mouse) was measured every other week. Tumor size was measured using 
digital calipers at the termination of the experiment. Treatment groups for this experiment 
are shown in Table 2.1. 
2.3.2 Diet study 
As shown in Figure 2.2, female ICR mice, 6 weeks of age (n = 30/group), were 
initiated with 25 nmol DMBA. Two weeks after initiation with DMBA, mice were started 
on diets containing UA (2 g/kg diet), Res (5 g/kg diet), Curc (10 g/kg diet), UA (2 g/kg) + 
Res (5 g/kg), UA (2 g/kg) + Curc (10 g/kg) or Res (5 g/kg) + Curc (10 g/kg) and/or given 
metformin in the drinking water (250 mg/kg bw). TPA (6.8 nmol) treatment began four 















Ace DMBA (25 nmol) Ace (200 µL) Ace (200 µL) Ace (200 µL) 
UA (2) + Ace DMBA (25 nmol) Ace (200 µL) UA (2 µmol) Ace (200 µL) 
Curc (2) + Ace DMBA (25 nmol) Curc (2 µmol) Ace (200 µL) Ace (200 µL) 
UA (2) + Curc (2) + Ace DMBA (25 nmol) Curc (2 µmol) UA (2 µmol) Ace (200 µL) 
TPA DMBA (25 nmol) Ace (200 µL) Ace (200 µL) TPA (6.8 nmol) 
UA (1) + TPA DMBA (25 nmol) Ace (200 µL) UA (1 µmol) TPA (6.8 nmol) 
UA (2) + TPA DMBA (25 nmol) Ace (200 µL) UA (2 µmol) TPA (6.8 nmol) 
Curc (1) + TPA DMBA (25 nmol) Curc (1 µmol) Ace (200 µL) TPA (6.8 nmol) 
Curc (2) + TPA DMBA (25 nmol) Curc (2 µmol) Ace (200 µL) TPA (6.8 nmol) 
UA (1) + Curc (1) + TPA DMBA (25 nmol) Curc (1 µmol) UA (1 µmol) TPA (6.8 nmol) 
UA (2) + Curc (1) + TPA DMBA (25 nmol) Curc (1 µmol) UA (2 µmol) TPA (6.8 nmol) 
UA (1) + Curc (2) + TPA DMBA (25 nmol) Curc (2 µmol) UA (1 µmol) TPA (6.8 nmol) 
UA (2) + Curc (2) + TPA DMBA (25 nmol) Curc (2 µmol) UA (2 µmol) TPA (6.8 nmol) 
Table 2.1: Treatment groups used for topical two-stage skin carcinogenesis assay 
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Figure 2.2: Diet study two-stage skin carcinogenesis protocol 
Group Initiation Diet/Water Treatment 
AIN-93M DMBA (25 nmol) AIN-93M [Control diet] Ace (200 µL) 
UA DMBA (25 nmol) UA (2 g/kg) Ace (200 µL) 
Res DMBA (25 nmol) Res (5 g/kg) Ace (200 µL) 
Curc DMBA (25 nmol) Curc (10 g/kg) Ace (200 µL) 
Met DMBA (25 nmol) AIN-93M + Met (250 mg/kg bw) Ace (200 µL) 
Met + UA DMBA (25 nmol) Met (250 mg/kg bw) + UA (2 g/kg) Ace (200 µL) 
Met + Res DMBA (25 nmol) Met (250 mg/kg bw) + Res (5 g/kg) Ace (200 µL) 
Met + Curc DMBA (25 nmol) Met (250 mg/kg bw) + Curc (10 g/kg) Ace (200 µL) 
UA + Res DMBA (25 nmol) UA (2 g/kg) + Res (5 g/kg) Ace (200 µL) 
UA + Curc DMBA (25 nmol) UA (2 g/kg)+ Curc (10 g/kg) Ace (200 µL) 
Res + Curc DMBA (25 nmol) Res (5 g/kg) + Curc (10 g/kg) Ace (200 µL) 
AIN-93M + TPA DMBA (25 nmol) AIN-93M [Control diet] TPA (6.8 nmol) 
UA + TPA DMBA (25 nmol) UA (2 g/kg) TPA (6.8 nmol) 
Res + TPA DMBA (25 nmol) Res (5 g/kg) TPA (6.8 nmol) 
Curc + TPA DMBA (25 nmol) Curc (10 g/kg) TPA (6.8 nmol) 
Met + TPA DMBA (25 nmol) AIN-93M + Met (250 mg/kg bw) TPA (6.8 nmol) 
Met + UA + TPA DMBA (25 nmol) Met (250 mg/kg bw) + UA (2 g/kg) TPA (6.8 nmol) 
Met + Res + TPA DMBA (25 nmol) Met (250 mg/kg bw) + Res (5 g/kg) TPA (6.8 nmol) 
Met + Curc + TPA DMBA (25 nmol) Met (250 mg/kg bw) + Curc (10 g/kg) TPA (6.8 nmol) 
UA + Res + TPA DMBA (25 nmol) UA (2 g/kg) + Res (5 g/kg) TPA (6.8 nmol) 
UA + Curc + TPA DMBA (25 nmol) UA (2 g/kg) + Curc (10 g/kg) TPA (6.8 nmol) 
Res + Curc DMBA (25 nmol) Res (5 g/kg) + Curc (10 g/kg) TPA (6.8 nmol) 
Table 2.2: Treatment groups used for diet study two-stage skin carcinogenesis assay 
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the duration of the experiment (30 weeks). Bodyweight, tumor incidence, tumor 
multiplicity and tumor size were measured as described in the topical experiment.  
Treatment groups used for this experiment are shown in Table 2.2. 
2.4 SHORT TERM TREATMENT PROTOCOL 
2.4.1 Topical experiment 
As shown in Figure 2.3, the dorsal skin of female ICR mice (7–9 weeks of age, n 
= 4-5/group) was shaved and then treated two days later with either Ace vehicle, UA (1 
μmol), Curc (2 μmol) or a combination of UA (1 μmol) + Curc (2 μmol) prior to TPA (6.8 
nmol) treatment (UA was applied 15 minutes prior and Curc was applied 30 minutes prior 
to TPA). All treatments were given twice weekly for two weeks. The treatment groups used 
for these experiments are shown in Table 2.3 
2.4.2 Diet study 
As shown in Figure 2.4, six week old, female, ICR mice were received and placed 
on AIN-76A diet for equilibration. One week later, mice were placed on diets containing 
UA (2 g/kg diet), Res (5 g/kg diet), Curc (10 g/kg diet), the combination of Curc (10 g/kg) 
and UA (2 g/kg), the combination of Res (5 g/kg) and UA (2 g/kg) or remained on the 
control diet (AIN-76A). One group received Met in the drinking water for comparison (250 
mg/kg bw per day). Four weeks later the dorsal skin of the mice was shaved two days prior 
to the first TPA treatment. TPA (6.8 nmol) was applied topically twice weekly for two 
weeks and Ace (200 µL) was used as the vehicle control. Treatment groups used for these 
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Ace Ace (200 µL) Ace (200 µL) Ace (200 µL) 
TPA Ace (200 µL) Ace (200 µL) TPA (6.8 nmol) 
UA (1 µmol) + TPA Ace (200 µL) UA (1 µmol) TPA (6.8 nmol) 
Curc (2 µmol) + TPA Curc (2 µmol) Ace (200 µL) TPA (6.8 nmol) 
Curc (2 µmol) + UA (1 µmol) + TPA Curc (2 µmol) UA (1 µmol) TPA (6.8 nmol) 
Table 2.3: Treatment groups for short term topical experiment  
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Figure 2.4: Short term diet study protocol 
 
Group Diet/Water Treatment 
AIN-76A AIN-76A [Control diet] Ace (200 µL) 
UA UA (2 g/kg) Ace (200 µL) 
Res Res (5 g/kg) Ace (200 µL) 
Curc Curc (10 g/kg) Ace (200 µL) 
UA + Res UA (2 g/kg) + Res (5 g/kg) Ace (200 µL) 
UA + Curc UA (2 g/kg)+ Curc (10 g/kg) Ace (200 µL) 
Met AIN-76A + Met (250 mg/kg bw) Ace (200 µL) 
AIN-76A + TPA AIN-76A [Control diet] TPA (6.8 nmol) 
UA + TPA UA (2 g/kg) TPA (6.8 nmol) 
Res + TPA Res (5 g/kg) TPA (6.8 nmol) 
Curc + TPA Curc (10 g/kg) TPA (6.8 nmol) 
UA + Res + TPA UA (2 g/kg) + Res (5 g/kg) TPA (6.8 nmol) 
UA + Curc + TPA UA (2 g/kg)+ Curc (10 g/kg) TPA (6.8 nmol) 
Met + TPA AIN-76A + Met (250 mg/kg bw) TPA (6.8 nmol) 
Table 2.4: Treatment groups used for short term diet study 
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experiments are shown in Table 2.4. 
2.5 HISTOLOGICAL ANALYSES 
Mice were treated as described in the short term protocols (Figures 2.3 and 2.4, 
Tables 2.3 and 2.4). BrdU (100 μg/g bw) was dissolved in PBS and injected i.p. to mice 
30 minutes prior to sacrifice. 48 hours after the last TPA treatment, the dorsal skin was 
fixed in 10% formalin-buffered solution, embedded in paraffin and sectioned for BrdU 
(Abcam, Cambridge, MA) or toluidine blue O (Fisher Scientific, Pittsburgh, PA) staining. 
The labeling index (LI) of the BrdU-stained sections was measured as previously described 
(117). Epidermal thickness was measured by taking the average of 20 measurements per 
skin section for each mouse. 
2.6 WESTERN BLOT ANALYSES 
Mice were treated as described in the short term treatment protocols (Figures 2.3 
and 2.4, Tables 2.3 and 2.4) and sacrificed two or six hours after the last TPA treatment. 
Epidermal tissue was collected and western blot analyses were performed using epidermal 
protein lysates as previously described (118). For some experiments, the nuclear fraction 
was extracted using Thermo Fisher (Waltham, MA) NE-PER™ Nuclear and Cytoplasmic 
Extraction Reagents according to the manufacturer’s protocol. Antibodies against the 
following proteins were purchased from Cell Signaling Technology (Danvers, MA): p-c-
JunS73 (#9164), c-Jun (#9165S), c-Fos (#2250), p-RbS780 (#9307), p-SrcY416 (#2101), Src 
(#2109), p-p70S6KT389 (#9234), p70S6K (#9202), Vinculin (#13901), GAPDH (#2118), 
p-Stat3Y705 (# 9145), p-Stat3S727 (#9134) and Stat3 (#9139). Antibodies against p-IκBαS32/36 
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(sc-101713), IκBα (sc-847), p-p50S337 (sc-101744) and p50 (sc-8414) were purchased from 
Santa Cruz Biotechnology (Dallas, TX). Cox-2 (160126) was purchased from Cayman 
Chemical (Ann Arbor, MI), EGFR (06-847) was purchased from Millipore (Burlington, 
MA), p-EGFRY1086 (ab5650) was purchased from AbCam (Cambridge, MA) and p27 
(610242) was purchased from BD Biosciences (Bradford, MA). 
2.7 QRT-PCR ANALYSES 
Mice were treated as described in the short-term protocol and sacrificed six hours 
after the last treatment. Epidermal RNA samples were isolated using TRIzol reagent 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. cDNA was then 
prepared using the High Capacity cDNA Reverse Transcription Kits (Applied Biosystems, 
Grand Island, NY) according to the manufacturer’s protocol. For qRT-PCR analysis, 2 μL 
of cDNA was mixed with 5 μL of 2X iTaq universal SYBR green supermix (Bio-Rad, 
Hercules, CA), 1 μL of 10 μM forward primers, 1 μL of 10 μM reverse primers and 1 μL 
of RNase-free water for a total volume of 10 μL. qRT-PCR reactions were performed and 
analyzed on a Viia 7 (Applied Biosystems, Carlsbad, CA) using the comparative CT 
method and normalized to GAPDH. 
2.8 MIR-21 ANALYSIS 
Mice were treated as described in the short-term protocol and sacrificed six hours 
after the last treatment. Epidermal RNA samples were isolated using TRIzol reagent 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. cDNA was then 
prepared using the TaqMan Advanced miRNA cDNA synthesis kit (Applied Biosystems, 
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Grand Island, NY) according to the manufacturer’s protocol. qRT-PCR reactions were 
performed using the TaqMan Advanced miRNA Assay (mmu-miR-21a-5p) according to 
the manufacturer’s protocol . Reactions were analyzed on a Viia 7 using the comparative 
CT method and normalized to miR-16-5p (has-miR-16-5p). 
2.9 STATISTICAL ANALYSIS 
The Mann–Whitney U test was used for analysis of tumor multiplicity, tumor size, 
LI, epidermal thickness, quantitation of Western blots, gene expression and mast cell 
infiltration. The Mantel–Cox test was used for analysis of tumor latency. Fisher’s exact 
test was used for analysis of tumor incidence. Significance in all cases was set at p ≤ 0.05. 
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Chapter 3: Inhibition of Skin Tumor Promotion by TPA with the 
Topical Combination of UA + Curc 
3.1 INTRODUCTION 
Despite the many advances that have been made in understanding cancer and 
developing new therapies, cancer is still the second leading cause of death in the US and 
accounts for about one in four deaths. Furthermore, approximately two out of five people 
will develop cancer in their lifetime, and in many cases cancer can be preventable (1). 
Aside from lifestyle choices such as avoiding tobacco products and maintaining a lean 
bodyweight, chemoprevention remains a strategy to reduce cancer risk, especially in high-
risk populations. Chemoprevention is the use of natural, synthetic, or biological agents to 
reverse, suppress or prevent the initial development of carcinogenesis or the progression to 
metastatic cancer (2). Phytochemicals have been widely studied as potential cancer 
chemopreventive agents given their abundance and overall relatively low toxicity (8-11). 
UA and Curc are two examples of phytochemicals that have been shown to inhibit 
tumor development as single agents in a two-stage skin carcinogenesis model, especially 
during the tumor promotion stage (67,68,85). UA is a pentacyclic triterpenoid found in 
plants and herbs such as Perilla frutescens (Japanese basil), rosemary, cranberries and the 
peels of apples (64,65). UA has been shown to possess many beneficial cancer prevention 
properties including anti-inflammatory, antioxidant and anti-proliferative activities 
(64,65). Curc, a polyphenol found in turmeric, has been shown to possess anti-
inflammatory and anti-oxidant activities, which are thought to play major roles in its 
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chemopreventive action (84). UA and Curc have low toxicity and are well tolerated in 
patients, making them ideal candidates as cancer prevention agents (119,120). 
A number of combinations of phytochemicals have now been tested and show 
increased anti-tumor activity when combined than when given as individual compounds. 
For example, our lab has previously shown that the combination of UA + Res inhibits skin 
tumor promotion to a greater extent than the compounds alone (67). Another study from 
our laboratory examined the combinations of UA + Curc, UA + Res and Res + Curc given 
in the diet and demonstrated a synergistic inhibition of tumor growth in an allograft prostate 
model (95). Xu et al. showed the combination of dietary Curc + green tea catechins 
provided greater inhibition of dimethylhydrazine-induced colon carcinogenesis than the 
individual compounds (121). These and many other studies demonstrate the greater 
potential for combinations of phytochemicals to be more effective as chemopreventive 
agents.  
For the current study, we applied UA and Curc individually as well as in 
combination topically during the tumor promotion phase before each TPA treatment to 
determine if the combination was more effective at inhibiting skin tumor development than 
the individual compounds. The results demonstrate that the combination of UA + Curc 
inhibited skin tumor promotion by TPA to a greater extent than either of the compounds 
alone, producing a significant combinatorial chemopreventive effect. The greater 
chemopreventive effect of the combination was associated with greater inhibition of both 
growth factor and inflammatory signaling pathways.  
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3.2 RESULTS 
3.2.1 Effect of UA, Curc and UA + Curc on skin tumor promotion by TPA  
A two-stage skin carcinogenesis assay was performed to examine the effects of UA, 
Curc, and the combination of UA + Curc on skin tumor promotion by TPA. We found that 
pretreatment with UA, Curc, and the combination significantly decreased final tumor 
multiplicity by  35%, 63%, and 75%, respectively, as shown in Fig. 1B (p < 0.05, Mann-
Whitney U test). In addition, the combination significantly reduced tumor multiplicity 
compared to the UA alone treated group (p < 0.05, Mann-Whitney U test). The final tumor 
incidence was reduced from 97% in the TPA treated group to 86% and 72% in the Curc 
and combination treated groups, respectively (Figure 3.1A). The reduction in tumor 
incidence by the combination of UA and Curc was significant compared to the TPA and 
UA + TPA groups (p < 0.05, Fisher’s exact test). Figure 3.1C shows that pretreatment with 
UA or Curc delayed the onset of tumor development compared to TPA (p < 0.05; Mantel-
Cox test). Furthermore, the combination significantly delayed the onset of tumor 
development to a greater extent than both UA and Curc alone (p < 0.05; Mantel-Cox test). 
Finally, the combination of UA + Curc significantly decreased tumor size and weight 
compared to TPA only, UA + TPA, and Curc + TPA treated groups (Figure 3.1E, F) (p < 
0.05, Mann-Whitney U test). No apparent toxicity was observed in any of the 
phytochemical treated groups, as there was no significant difference in bodyweight 
between the different treatments (Figure 3.1D). Overall, these results show that the 
combination of UA + Curc provided greater inhibition of skin tumor promotion by TPA 
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Figure 3.1: Effect of UA and Curc on skin tumor promotion by TPA  
Female ICR mice 7 weeks old (n = 30/group) were initiated with 25 nmol DMBA. Two 
weeks after initiation with DMBA, mice were pretreated with Ace vehicle, UA (1 μmol), 
Curc (2 μmol) or the combination of UA (1 μmol) + Curc (2 μmol) prior to TPA (6.8 
nmol) treatment. All treatments were given twice-weekly for the remainder of the 
experiment (25 weeks).  A. Tumor multiplicity.  B. Tumor incidence.  C. Tumor latency 
shown using a Kaplan Meier curve of tumor free mice.  D. Average bodyweight (g) per 
mouse.  E. Average surface area of tumors (mm2).  F. Average tumor weight (mg). * 
Significant when compared to Ace + TPA group; †, Significant when compared to UA + 
TPA; #, Significant when compared to Curc + TPA; (p < 0.05). Mann-Whitney U test 
was used for analysis of tumor multiplicity, tumor size and tumor weight, Fisher’s exact 
test was used for analysis of tumor incidence, and Mantel-Cox test was used for analysis 
of tumor latency.
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than either of the compounds alone.  
3.2.2 Effect of UA, Curc and UA + Curc on TPA-induced epidermal 
hyperproliferation 
UA, Curc and the combination significantly decreased TPA induced epidermal 
hyperproliferation as shown in Figure 3.2. Pretreatment with UA or Curc alone 
significantly reduced LI from 15.20% in the TPA only group to 11.03% and 11.07%, 
respectively, and epidermal thickness from 44.81 μm in the TPA only group to 34.69 μm 
and 33.45 μm (p ≤ 0.05; Mann-Whitney U test)(Figure 3.2B,C). The combination of UA 
+ Curc further reduced LI to 7.02% and epidermal thickness to 25.86 μm, which was 
significantly lower than the TPA only, UA + TPA and Curc + TPA groups (p ≤ 0.05; Mann-
Whitney U test). These results demonstrate that the combination of UA + Curc was more 
effective than either of the compounds given alone at reducing TPA-induced epidermal cell 
proliferation. 
3.2.3 Effect of UA, Curc and UA + Curc on TPA-induced epidermal signaling 
pathways 
TPA induces activation of a number of signaling pathways that are required for the 
promotion of skin tumors in the two-stage model (22).  Using the short-term protocol, we 
investigated which signaling pathways were most impacted by the combination of UA + 
Curc. As presented in Figure 3.3, TPA induced increased phosphorylation of EGFR, Src, 
p70S6K, c- Jun, IκBα, NF-κB p50 and Rb as well as increased total protein levels of c-Jun, 





Figure 3.2: Effect of UA, Curc and the combination of UA + Curc on TPA-induced 
epidermal hyperproliferation and hyperplasia  
The dorsal skin of female ICR mice (7–9 weeks of age; n = 8/group) was shaved and then 
two days later treated with either acetone vehicle, UA (1 μmol), Curc (2 μmol) or a 
combination of UA (1 μmol) + Curc (2 μmol) prior to TPA (6.8 nmol) treatment. All 
treatments were given twice-weekly for two weeks. Forty-eight hours after the last TPA 
treatment, dorsal skin was fixed in 10% formalin-buffered solution, embedded in paraffin 
and sectioned for BrdU-staining.  A. Representative BrdU-stained sections of dorsal skin. 
Arrows indicate BrdU stained cells in the epidermis.  B. Quantitative evaluation (mean ± 
SEM) of epidermal hyperproliferation (BrdU incorporation).  C. Quantitative evaluation 
(mean ± SEM) of hyperplasia (epidermal thickness). *, Significant when compared to 
TPA group; †, Significant when compared to UA + TPA; #, Significant when compared 
to Curc + TPA; (p ≤ 0.05, Mann-Whitney U test).  
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Pretreatment with Curc alone significantly decreased phosphorylation of p70S6K and NF-
κB p50, decreased total levels of NF-κB p50 and increased levels of p27 compared to the 
TPA only group. Pretreatment with UA alone significantly decreased phosphorylation of 
IκBα and NF-κB p50 and increased levels of p27 compared to the TPA only group.  
Notably, when both compounds were given together before TPA treatment, the 
combination significantly decreased phosphorylation of EGFR, Src, p70S6K, c-Jun, IκBα, 
NF-κB p50 and Rb compared to the TPA only group. The combination also significantly 
reduced protein levels of c-Jun, c-Fos NF-κB p50 and Cox-2 compared to the TPA only 
group.  When compared to the individual compounds, the most significant effects of the 
combination were seen on phosphorylation of EGFR, Src, c-Jun, IκBα and Rb and on total 
levels of c-Jun, c-Fos and Cox-2.  Thus, the combination significantly inhibited a much 
broader range of target pathways known to play an important role in skin tumor promotion. 
Since NF-κB, c-Jun and c-Fos are transcription factors, further experiments were 
performed to examine the status of their nuclear localization following treatment with the 
combination. Indeed we found, particularly with the combination of UA + Curc, that the 
nuclear levels of c-Fos, c-Jun, p-c-JunSer73, NF-κB p50 and p-NF-κB p50Ser336 were all 
decreased (Figure 3.4). Finally, although the individual compounds showed no effect on 
phosphorylation of Stat3, the combination of UA + Curc significantly reduced tyrosine 





Figure 3.3: Effect of UA, Curc and the combination of UA + Curc on TPA-induced signaling 
pathways  
The dorsal skin of female ICR mice (7–9 weeks of age; n = 4-5/group) was shaved and then two 
days later treated with either acetone vehicle, UA (1 μmol), Curc (2 μmol) or a combination of 
UA (1 μmol) + Curc (2 μmol) prior to TPA (6.8 nmol) treatment. Six hours after the last TPA 
treatment, epidermal lysates were prepared for Western blot analyses (pooled groups).  A, 
Representative Western blots.  B, Quantitation of Western blots (mean ± SEM; average of at 
least 3 independent experiments). *, Significant when compared to TPA group; †, Significant 
when compared to UA + TPA; #, Significant when compared to Curc + TPA; (p ≤ 0.05, Mann-
Whitney U test). 
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Figure 3.4: Effect of the combination of UA + Curc on TPA-induced signaling in the 
nucleus 
The dorsal skin of female ICR mice (7–9 weeks of age) was shaved and then two days 
later treated with either acetone vehicle, UA (1 μmol), Curc (2 μmol) or a combination of 
UA (1 μmol) + Curc (2 μmol) prior to TPA (6.8 nmol) treatment. Six hours after the last 
TPA treatment, the nuclear fractions from epidermal lysates were prepared for Western 
blot analyses. A. Representative Western Blots. B. Quantitation of Western blots. Graph 




Figure 3.5: Effect of the combination of UA + Curc on TPA-induced Stat3 signaling 
The dorsal skin of female ICR mice (7–9 weeks of age) was shaved and then two days 
later treated with either acetone vehicle, UA (1 μmol), Curc (2 μmol), or a combination 
of UA (1 μmol) and Curc (2 μmol) prior to TPA (6.8 nmol) treatment. Two hours after 
the last TPA treatment, epidermal lysates were prepared for Western blot analysis 
(pooled groups).  A, Representative Western blots.  B, Quantitation of Western blots. *, 
Significant when compared to TPA group (p ≤ 0.05, Mann-Whitney U test).    
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3.2.4 Effect of UA, Curc and UA + Curc on infiltration of mast cells and 
inflammatory gene expression 
The effects of UA, Curc and the combination on inflammation were investigated 
using the short-term protocol. Figure 3.6 shows that TPA increased levels of mRNAs in 
the epidermis for a number of inflammatory markers genes including IL-1β, IL-6, IL-19, 
IL-22, CXCL2 and Cox-2. In addition, TPA treatment increased levels of VEGFA, an 
angiogenesis factor. Although at the dose given, UA alone did not provide significant 
inhibition of most of the inflammatory genes analyzed, it did significantly reduce levels of 
Cox-2 mRNA (p ≤ 0.05). Curc treatment alone provided more inhibition and significantly 
decreased the expression of IL-6, IL-19, Cox-2 and VEGFA (p ≤ 0.05). The combination 
of UA + Curc was more effective than the individual compounds alone and inhibited the 
expression of IL-1β, IL-6, IL-19, IL-22, CXCL2, Cox-2 and VEGFA (p ≤ 0.05). 
Furthermore, the combination provided significantly more inhibition than UA alone for IL-
19, Cox-2 and VEGFA and was significantly better than both UA and Curc alone for 
reducing IL-1β, IL-6, IL-22 and CXCL2 mRNAs (p ≤ 0.05). The infiltration of mast cells 
into the dermis was also evaluated (Figure 3.7). Pretreatment with both UA and Curc alone 
significantly inhibited the infiltration of mast cells into the dermis (p ≤ 0.05). Moreover, 
the combination of UA +  Curc provided further inhibition of mast cell infiltration that was 
significantly reduced compared to  the TPA treated group and compared to the effects of 
UA or Curc alone (p ≤ 0.05). These experiments show that both UA and Curc alone 
significantly reduced TPA-induced inflammation but that the combination provided a 




Figure 3.6: Effects of UA, Curc and the combination of UA + Curc on TPA-induced gene 
expression  
The dorsal skin of female ICR mice (7–9 weeks of age; n = 4-5/group) was shaved and 
then two days later treated with either acetone vehicle, UA (1 μmol), Curc (2 μmol) or a 
combination of UA (1 μmol) + Curc (2 μmol) prior to TPA (6.8 nmol) treatment. All 
treatments were given twice-weekly for two weeks. Six hours after the last TPA 
treatment, epidermal lysates were prepared for RNA isolation. Graphs show qRT-PCR 
analyses of gene expression of IL-1β, IL-6, IL-19, IL-22, CXCL2, Cox-2 and VEGFA. 
Graphs represent mean ± SEM (average of at least 3 independent experiments). *, 
Significant when compared to TPA group; †, Significant when compared to UA + TPA; 





Figure 3.7: Effect of UA, Curc and the combination of UA + Curc on TPA-induced 
infiltration of mast cells. 
The dorsal skin of female ICR mice (7–9 weeks of age; n = 3/group) was shaved and then 
two days later treated with either acetone vehicle, UA (1 μmol), Curc (2 μmol) or a 
combination of UA (1 μmol) + Curc (2 μmol) prior to TPA (6.8 nmol) treatment. All 
treatments were given twice-weekly for two weeks. Forty-eight hours after the last TPA 
treatment, dorsal skin was fixed in 10% formalin-buffered solution, embedded in paraffin 
and sectioned for toluidine blue O staining.  A, Representative toluidine blue O stained 
sections of dorsal skin. Arrows indicate mast cells.  B, Quantitative evaluation (mean ± 
SEM) of mast cell infiltration in dermis. *, Significant when compared to TPA group; †, 
Significant when compared to UA + TPA; #, Significant when compared to Curc + TPA; 
(p ≤ 0.05, Mann-Whitney U test).  
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3.2.5 The combination of UA and Curc inhibit expression of miR-21 
UA and Curc were also evaluated for their effects on expression of miR-21. miR-
21 is a microRNA upregulated in many cancers, including breast, colon, lung, pancreas, 
prostate, and stomach, and has been shown to be involved in the two-stage skin 
carcinogenesis mouse model (122,123).  As shown in Figure 3.8, TPA treatment induced 
a significant increase in miR21 levels. At the doses used in this experiment, the individual 
compounds did not provide any inhibition whereas the combination significantly reduced 
the levels of miR21a-5p. 
3.3 DISCUSSION 
In this study, we have demonstrated that the combination of topically applied UA 
+ Curc inhibited skin tumor promotion by TPA to a greater extent than the individual 
compounds given alone. The most prominent effects with the combination compared to the 
individual compounds were seen on tumor free survival, tumor size and tumor weight. 
Additional investigation corroborated these findings and showed that the combination 
significantly inhibited TPA-induced epidermal hyperproliferation and hyperplasia 
compared to the compounds alone. Furthermore, the combination inhibited a broad range 
of signaling pathways involved in cell growth, proliferation and inflammation. For 
example,  the combination significantly reduced phosphorylation of EGFR, Src, p70S6K, 
c-Jun, Iκ-Bα, NF-κB p50, Stat3 and Rb as well as protein levels of c-Jun, c-Fos and Cox-




Figure 3.8: The effect of the combination of UA + Curc on TPA-induced expression of 
miR-21 
The dorsal skin of female ICR mice (7–9 weeks of age) was shaved and then two days 
later treated with either acetone vehicle, UA (1 μmol), Curc (2 μmol) or a combination of 
UA (1 μmol) and Curc (2 μmol) prior to TPA (6.8 nmol) treatment. Six hours after the 
last TPA treatment, epidermal lysates were prepared for qPCR analysis. Graph show 
qRT-PCR analysis of gene expression of miR-21a-5p. Graph represent mean ± SEM 
(average of at 4 independent experiments). *, Significant when compared to TPA group 
(p ≤ 0.05, Mann-Whitney U test).   
 40 
TPA-induced expression of miR-21. mRNA levels of inflammatory genes IL-1β, IL-6, IL-
22 and CXCL2 were also significantly decreased by the combination compared to the 
compounds alone. Finally, the combination significantly inhibited mast cell infiltration into 
the dermis compared to the compounds alone. Collectively, these data demonstrate a strong 
anti-proliferative and anti-inflammatory effect with the combination of UA + Curc that 
correlated with its greater effects on tumor promotion compared to the individual 
compounds.  
As mentioned in the introduction, a  combination of UA + Curc given in the diet 
was shown to synergistically inhibit growth of mouse prostate cancer cells (HMVP2 cells) 
in a tumor allograft model (95). In these earlier studies, while not all of the same pathways 
examined in the current study were investigated, the combination of UA + Curc inhibited 
phosphorylation of Src, Stat3 and p70S6K in the HMVP2 tumor cells to a greater extent 
than either compound alone. The combination also increased apoptosis more than the 
individual compounds alone in both HMVP2 and DU145 cells as shown by an increase in 
annexin V staining and cleaved PARP (95). In the current study, there was no strong 
indication of an increase in apoptosis by the combination of UA + Curc at the 2 and 6 hour 
time points with the doses given (data not shown), indicating that in the skin model the 
inhibitory activity seemed to be due more to an inhibition of proliferation and 
inflammation. Nevertheless, inhibition of some of the same pathways in epidermis with the 
combination of UA + Curc after topical application supports the importance of these 
mechanisms and provides evidence that this combination could be effective at preventing 
other cancers as well. 
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As noted in the Introduction, previous work from our laboratory showed that the 
combination of UA + Res significantly inhibited skin tumor promotion by TPA to a greater 
extent than UA or Res alone (67). In the present study a lower dose of UA was used (1 
µmol vs. 2 µmol in previous study). Similar effects with the combination of UA + Curc 
and the combination of UA + Res were seen on decreasing phosphorylation EGFR, Src and 
c-Jun. Although UA + Res seemed to provide more inhibition of NF-κB p65 and UA + 
Curc provided more inhibition of NF-κB p50, both combinations effectively inhibited NF-
κB signaling and decreased levels of one of its transcriptional targets Cox-2 as well as gene 
expression of IL-1β and Cox-2. One difference seen was that the combination of UA + Res 
inhibited phosphorylation of JNK 1/2 and p38, which was not seen with the combination 
of UA + Curc. Also, the combination of UA + Curc decreased phosphorylation of Rb and 
increased levels of p27, whereas the combination of UA + Res increased levels of p21. 
Although some differences were present in the mechanism of how the combinations were 
acting, both UA + Curc and UA + Res effectively inhibited skin tumor promotion by TPA 
to a greater extent than their respective compounds alone. These findings highlight the 
importance of inhibiting EGFR, Src, c-Jun and NF-κB during skin tumor promotion by 
TPA. 
AP-1 is a transcription factor composed of Jun and Fos family members and is 
known to be important for skin carcinogenesis and skin tumor promotion (59). 
Furthermore, AP-1 is involved in a number of processes including differentiation, 
proliferation, and transformation (52). In this study, the combination of UA + Curc 
significantly inhibited phosphorylation of c-Jun as well as total levels of c-Jun and c-Fos 
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induced by TPA treatment. Thus, reduction in AP-1 activity appears to be an important 
part of the inhibitory effects of the combination on skin tumor promotion.  A similar effect 
was also seen in our previous studies with a combination of UA + Res where AP-1 activity 
was significantly reduced (67). The reduction in phosphorylation of c-Jun as well as total 
levels of c-Jun and c-Fos induced by TPA treatment  seen with the combination correlated 
with a decrease in epidermal proliferation as seen by the reduction in BrdU incorporation 
(Figure 3.2).  
Inflammation is a critical component of tumorigenesis, in part by creating a tumor 
promoting  microenvironment conducive to tumor growth (124). NF- κB plays a major role 
in inflammatory signaling and tumor development, and this pathway is inhibited by Curc 
(125,126). In the present study, the combination of UA + Curc significantly inhibited 
phosphorylation of IκBα and NF-κB p50 as well as total levels of NF-κB p50. This 
inhibition of NF-κB signaling likely contributed to the decrease in protein levels of Cox-2 
as well as reduced expression of inflammatory genes such as Cox-2, IL-1β and IL-6, as 
NF-κB is known to induce transcription of these genes (127-129). Both NF-κB and Cox-2 
signaling pathways play critical roles in skin tumor promotion by TPA and other tumor 
promoters (26,61,62). 
As mentioned above miR-21 is a microRNA upregulated in many cancers and is 
involved in the two-stage skin carcinogenesis mouse model (122,123). It negatively 
regulates targets such as the tumor suppressors Pdcd4, Sprouty 1 or Sprouty 2 (130-132). 
However, in our experiments we did not see a significant increase in Pdcd4, Sprouty 1 or 
Sprouty 2 (data not shown) by the combination of UA + Curc. Further experiments will 
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need to be done to elucidate whether the inhibition of miR-21 by UA + Curc is an important 
mechanism of its inhibitory action and whether Pdcd4, Sprouty 1 or Sprouty 2 are increased 
by UA + Curc at later timepoints. 
Phytochemicals are ideal candidates for chemoprevention because they are 
relatively safe, act on a broad spectrum of signaling pathways and are inexpensive (8). In 
general, it is believed that combinations of phytochemicals will provide greater effects than 
single compounds. There are now a number of studies that demonstrate this idea. For 
example, as mentioned above, the combination of UA + Curc synergistically inhibited 
tumor growth of prostate cancer cells in an allograft model (95). In the same study, the 
combinations of UA + Res and Curc + Res also produced synergistic inhibition of tumor 
growth (95). Another previous study in our lab, mentioned above, showed the combination 
of UA +  Res inhibited skin tumor promotion by TPA to a greater extent than either 
compound alone (67). Jin et al showed the combination of curcumin and epigallocatechin-
3-gallate (EGCG) suppressed colorectal carcinoma PDX tumor growth to a greater extent 
than either compound alone (133). Another example is the combination of luteolin and 
EGCG that inhibited xenograft tumor growth of a head and neck squamous cell carcinoma 
cell line to a greater extent than either compound alone (134). Generally, because certain 
combinations are more effective than their respective individual compounds, they can be 
expected to provide greater chemopreventative activity and at lower doses. 
In conclusion, the current study demonstrates that the combination of UA + Curc 
given topically provides greater inhibition of skin tumor promotion by TPA than either 
compound given alone. Mechanistically, this was associated with significant anti-
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inflammatory and anti-proliferative effects. These results reveal the potential for the 
combination of UA + Curc to be used for chemopreventative strategies for a number of 
cancers, including non-melanoma skin cancer. 
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Chapter 4: Evaluating the effects of UA, Curc, Res and the 
Combination in the Diet on Skin Tumor Promotion by TPA 
4.1 INTRODUCTION 
UA, Res and Curc have all been shown to inhibit skin tumor promotion by TPA 
when applied topically (82,85,103). Furthermore, when given in the diet these compounds 
have shown to inhibit tumor development in various mouse models. For example, UA in 
the diet inhibited tumorigenesis in the transgenic adenocarcinoma of mouse 
prostate (TRAMP) mouse model and a postmenopausal breast cancer mouse model 
(69,71). Res in the diet inhibited tumorigenesis in a sporadic model of colorectal cancer, 
DMBA-induced mammary carcinogenesis and a two-stage model of rat 
hepatocarcinogenesis (104,105,107). Curc given in the diet inhibited tumor development 
in K-ras-induced lung cancer in mice (87). However, the ability of UA, Res and Curc to 
inhibit tumor development in the two-stage skin carcinogenesis when administered in the 
diet has not been evaluated to our knowledge.  
We receive a plethora of phytochemicals from many fruits and vegetables in our 
diets, not just a single phytochemical alone. It is believed that receiving these combinations 
of phytochemicals provides us with a stronger chemopreventive effect than a single agent 
alone. In Chapter 3 I showed that the topical administration of the combination of UA and 
Curc provided greater inhibition of skin tumor promotion by TPA than the compounds 
alone. Our lab has also shown this to be true for the combination of UA and Res (67). 
Furthermore, we showed that the combinations of UA + Curc, UA + Res and Res + Curc 
 46 
when given in the diet inhibited tumor growth in a xenograft prostate mouse model to a 
greater extent than the compounds alone (95).  
In this study we wanted to investigate whether dietary administration of UA, Res 
and Curc as single agents inhibit skin tumor promotion by TPA. In addition we wanted to 
examine whether combinations of these phytochemicals in the diet provide further 
inhibition of skin tumor promotion. Finally, we analyzed whether the compounds in the 
diet combined with Met in the drinking water provided greater inhibition of skin tumor 
promotion. 
4.2 RESULTS 
 Initial short term experiments suggested UA, Res, Curc and their combinations in 
the diet inhibited signaling pathways involved in tumorigenesis (Figures 4.1, 4.2). UA, 
Res, Curc, UA + Res and UA + Curc appeared to decrease phosphorylation of EGFR. The 
combination of UA + Res decreased phosphorylation of c-Jun and Res alone decreased 
total levels of c-Jun. Dietary administration also seemed to downregulate NF-κB signaling. 
The combinations of UA + Res and UA + Curc decreased both total levels and 
phosphorylation of NF-κB p50. Furthermore, the combination of UA + Curc decreased 
levels of the transcriptional target of NF-κB, Cox-2. Finally, Curc, UA + Res and UA + 
Curc inhibited phosphorylation of Rb (Figure 4.2). The decreases in these signaling 
pathways correlated with a reduction of TPA-induced epidermal hyperproliferation by Res, 
Curc, UA + Res and UA + Curc (Figure 4.3). 
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Figure 4.1: Effects of UA, Curc and Res in the diet on EGFR, c-Jun, NF-κB and Cox-2 
Mice were treated according to the short term diet study protocol. A. Representative 
Western blots. B. Quantitation of Western blots.  
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Figure 4.2: Effect of UA, Curc and Res in the diet on phosphorylation of Rb 
Mice were treated according to the short term treatment protocol. A. Representative 





Figure 4.3: Effect of UA, Curc and Res in the diet on TPA-induced hyperproliferation 
Mice were treated according to the short term protocol. Quantitative evaluation (mean ± 
SEM) of epidermal hyperproliferation (BrdU incorporation). *, Significantly different 
from AIN76A + TPA group (p < 0.05).  
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 Based on these preliminary findings a two-stage skin carcinogenesis assay was 
performed with these compounds in the diet. Contrary to our hypothesis, there were no 
significant differences in tumor incidence, tumor multiplicity or onset of tumor 
development compared to the TPA group (Figure 4.4). Res alone in the diet did however 
significantly reduce tumor size and weight compared to the TPA group (Figure 4.4 C, D). 
Furthermore, the combinations (UA + Res, UA + Curc, Res + Curc) provided no further 
inhibition than the compounds alone (Figure 4.5). UA, Res and Curc were also 
investigated in combination with Met, but again we did not see any further inhibition with 
the combinations (Figure 4.6).  
4.3 DISCUSSION 
 In preliminary short term experiments, UA, Res, Curc and the combinations 
administered in the diet reduced phosphorylation of EGFR, c-Jun, NF-κB p50 and Rb and 
total levels of c-Jun, NF-κB p50 and Cox-2. However, at the doses given, the compounds 
in the diet did not significantly reduce tumor incidence or tumor multiplicity or delay the 
onset of tumor development and the combinations did not provide any further inhibition 
than the compounds alone. On the other hand, Res in the diet did significantly reduce tumor 
size and tumor weight, indicating it is providing some inhibition on skin tumor promotion 
by TPA. 
It could be that the doses given were not high enough to produce an anti-tumor 
effect in the skin. Also, because the compounds were given in the diet, metabolism, 
absorption, distribution to the skin and clearance become an issue. Curc is known to be 
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Figure 4.4: Effect of UA, Curc and Res as single agents in the diet on skin tumor 
promotion by TPA 
Mice were treated according to the diet study two-stage skin carcinogenesis assay. A. 
Tumor incidence.  B. Tumor multiplicity.  C. Tumor latency shown using a Kaplan Meier 
curve of tumor free mice.  D, Average bodyweight (g) per mouse.  E, Average surface 
area of tumors (mm2).  F, Average tumor weight (mg). * Significant when compared to 
TPA group. Mann-Whitney U test was used for analysis of tumor multiplicity, tumor size 




Figure 4.5: Effects of combinations of UA, Curc and Res on skin tumor promotion 
by TPA 
Mice were treated according to the diet study skin carcinogenesis assay.  A. Tumor 
multiplicity for the combination of UA + Res given in the diet.  B. Tumor multiplicity for 
the combination of UA + Curc given in the diet.  C. Tumor multiplicity for the 




Figure 4.6: Effects of UA, Curc or Res in combination with Met on skin tumor 
promotion by TPA 
Mice were treated according to the diet study skin carcinogenesis assay.  A. Tumor 
multiplicity for the combination of Met given in the drinking water and UA given in the 
diet.  B. Tumor multiplicity for the combination of Met given in the drinking water and 
Res given in the diet.  C. Tumor multiplicity for the combination of Met given in the 
drinking water and Curc given in the diet. * Significant when compared to TPA group 
(Mann-Whitney U, p < 0.05).  
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poorly absorbed and metabolized quickly, requiring high doses to be detected in the serum 
(135). For example, in one clinical trial, patients receiving 2.2 g of Curc per day did not 
have any detectable levels of Curc in the blood (119). UA is hydrophobic, and therefore 
not very well absorbed, and has limited bioavailability (136). Res is fairly well absorbed, 
however its metabolism leads to poor bioavailability (137).  
 Many different strategies have been employed to increase the bioavailability of UA, 
Curc and Res. For example, studies have been done to package UA, Curc and Res in 
nanoparticles and liposomes (138-141). Furthermore, several synthetic analogs have been 
developed to help improve Curc’s solubility and inhibit its rapid metabolism (142). 
Another tactic has been to add other compounds to improve bioavailability. Curc has been 
co-encapsulated with piperine, which is thought to improve Curc’s absorption (143). Res 
has also been co-administered with piperine, which increased the bioavailability of Res by 
delaying its glucuronidation and therefore slowing its metabolism (144). 
 Overall these experiments did not demonstrate that UA or Curc at the doses given 
in the diet inhibit skin tumor promotion by TPA. Furthermore, UA, Curc and Res given in 
various combinations, or in combination with Met, did not provide additional inhibition of 
skin tumor promotion. Res in the diet did significantly inhibit tumor size and weight to 
levels that were comparable with Met, signifying it is providing some growth inhibition of 
tumorigenesis, but is not inhibiting the initial tumor development. Further experiments will 
need to be done to investigate why UA, Curc and Res given in the diet did not significantly 
inhibit skin tumor promotion by TPA. 
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Chapter 5: Summary, significance and future directions 
 Overall I found that the combination of topically applied UA + Curc significantly 
inhibited skin tumor promotion by TPA to a greater extent that either compound alone. 
Notably, the combination significantly delayed the onset of tumor development and 
inhibited tumor size and weight significantly more than either UA or Curc given as 
individual compounds. UA + Curc inhibited skin tumor development by acting by a strong 
anti-proliferative and anti-inflammatory mechanism. EGFR, c-Fos, c-Jun, Src, NF-κB and 
Stat3 seem to be the most important targets for the inhibitory effects of this combination. 
Furthermore, the inhibition of NF-kB led to a reduced expression of inflammatory 
cytokines from the keratinocytes which play an important role in dermal inflammation 
induced by TPA during the process of tumor promotion. This study highlights the potential 
of the combination of UA + Curc to be used in chemopreventive strategies. 
 We next examined the effects of UA, Curc and Res given in the diet on skin tumor 
promotion by TPA as a more relevant model of how humans would be exposed to these 
compounds. Contrary to our preliminary results which suggested UA, Curc and Res in the 
diet were inhibiting EGFR, c-Jun, NF-κB p50 and Rb, we found that these compounds did 
not inhibit skin tumor promotion by TPA at the doses given when administered in the diet. 
Moreover, combinations of the phytochemicals did not produce further inhibition and 
combining the phytochemicals with Met did not provide any further inhibition. Res did 
significantly reduce tumor size and weight to an extent similar to Met, suggesting it is 
providing some growth inhibition of the tumors, but not the initial onset of tumor 
development. Further experiments discussed below will need to be done to investigate why 
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UA, Curc and Res did not inhibit skin tumor promotion by TPA when administered in the 
diet. 
5.1 FUTURE DIRECTIONS 
 The transcription factors c-Fos, c-Jun, NF-κB and Stat3 seem to play an important 
role in the anti-tumor activity of the combination of topically applied UA + Curc. AP-1, 
NF-κB and Stat3 have been shown to play critical roles in skin tumor promotion by TPA 
(59,61,117). It would be valuable to further examine the importance of these transcription 
factors in the inhibitory effect of UA + Curc. Both overexpressing and knocking out or 
inhibiting c-Fos, c-Jun, NF-κB or Stat3 would further reveal the mechanism by which UA 
+ Curc is inhibiting tumorigenesis.  
 Although we saw a significant decrease in miR-21 expression with the combination 
of UA + Curc, we did not see a significant increase in targets known to be inhibited by 
miR-21 such as the tumor suppressors Pdcd4, Sprouty 1 or Sprouty 2 (130-132). Additional 
experiments will need to be done to investigate these effects on miR-21 and downstream 
targets. It could be that the 6 hour timepoint was not the ideal time to see the increase of 
Pdcd4, Sprouty 1 or Sprouty 2. A time course experiment would allow us to investigate 
whether the inhibition of miR-21 is an important mechanism of the inhibitory action of UA 
+ Curc and whether this inhibition produces a subsequent increase in Pdcd4, Sprouty 1 or 
Sprouty 2. 
 Further experiments with the diet studies need to be done to investigate why UA, 
Curc and Res did not inhibit skin tumor promotion by TPA when given in the diet. One 
 56 
question that needs to be addressed is whether these compounds are bioavailable and 
reaching the skin at the doses given. Serum and tissues, including skin, kidney, liver, 
pancreas and lung were collected after 4, 19 and 31 weeks on the diets. It would be of 
interest to examine the levels of UA, Curc and Res both in the serum and skin. If the levels 
of these phytochemicals are low in the serum and skin, other options would need to be 
examined to increase their bioavailability. For example, we could explore packaging them 
in nanoparticles, using synthetic analogs or co-administering with other compounds to 
increase their absorption.  
 Finally, the dose of Met used in the diet studies was very effective alone and we 
did not see any further inhibition of tumor development when combined with UA, Curc or 
Res. It would be beneficial to test lower doses of Met to allow us to see potential 
combinatorial effects when combined with UA, Curc or Res. 
 These studies would allow us to further explore the potential of UA, Curc and Res 
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